Innovations Abound - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Innovations Abound

Pharmaceutical Technology

Here's a look at some of the most interesting and thematic responses you—our readers—provided for Pharmaceutical Technology's anniversary survey of industry advances and directions.

Which events significantly affected or caused changes in pharmaceutical manufacturing?
"My graduation from college."

"Better chemistry," "gene technology," and "train(ing) dogs to sniff counterfeit drugs" will impact the future direction of pharmaceutical manufacturing.

The rationalization of small-molecule manufacturing facilities in APIs.
"Is the leading edge of pharma."

On the use of information technology:
"There is no replacement for an advanced and validated computerized system."

When it comes to formulation development and manufacturing practices.
"The advice from our management is to have 50% of our workload outsourced—and especially routine work."

Thanks to advanced analytical technologies in NIR.
"(we) don't actually need to prepare the sample tediously."

With regard to the GMPs for the 21st century.
"It's been a long time since 1978, and it is time to update."

"...Most companies have found a way around..."
21 CFR Part 11 regulation.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here